Header and Body 4

Advantages

  • ML278 and ML279 are selective, reversible, and potent inhibitors of SR-BI
  • The lead compounds have superior potency compared to the clinical compound ITX-5061
  • Inhibitors of SR-BI could be potential therapeutic agents to treat atherosclerosis and HCV and malarial infections.